Last reviewed · How we verify
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy
The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy plus HIPEC is superior to only radical gastrectomy in terms of overall survival.
Details
| Lead sponsor | Wuhan University |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2015-08 |
| Completion | 2020-03-10 |
Conditions
- Malignant Neoplasm of Stomach
Interventions
- Hyperthermic intraperitoneal chemotherapy (HIPEC)
- D2 radical gastrectomy
- SOX postoperative chemotherapy
- XELOX postoperative chemotherapy
Primary outcomes
- overall survival — 5 years
From the date of surgery to the date of death or to the end of follow-up
Countries
China